Accumulating evidence has shown that ASXL1 mutations inhibit cancer cell differentiation and that SETBP1 mutations promote cell proliferation, thus leading to AML progression (Inoue et al., 2015; Makishima et al., 2013; Saika et al., 2018). Here, SETBP1 is linked to acute myeloid leukemia.